Results 111 to 120 of about 1,590 (229)

The Danish Out‐of‐Hospital Cardiac Arrest Trial: A Statistical Analysis Plan

open access: yesActa Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Post‐cardiac arrest care for patients resuscitated from out‐of‐hospital cardiac arrest (OHCA) includes multiple pharmacological and physiological interventions, yet optimal strategies to reduce post‐cardiac arrest syndrome–related morbidity and mortality remain uncertain.
Simon Mølstrøm   +11 more
wiley   +1 more source

Prophylactic Olanzapine Versus Placebo in Comatose Survivors of Out‐of‐Hospital Cardiac Arrest: Protocol for a Multicenter Randomized Comparison Within the Danish Out‐of‐Hospital Cardiac Arrest (DANOHCA) Trial

open access: yesActa Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Delirium is a frequent complication in comatose Out‐of‐Hospital Cardiac Arrest (OHCA) survivors requiring postresuscitation intensive care and is associated with higher mortality and longer hospitalization. Despite this, there is no established pharmacologic strategy for delirium prevention in OHCA survivors.
Benedikte Liebetrau   +12 more
wiley   +1 more source

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP‐1 Receptor Agonist Therapy

open access: yesActa Paediatrica, Volume 115, Issue 8, Page 1726-1736, August 2026.
ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez   +11 more
wiley   +1 more source

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial

open access: yesClinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Olamkicept is a first‐in‐class fully human fusion protein that selectively inhibits trans interleukin (IL)‐6 signaling. Previous phase I clinical trials demonstrated that single doses up to 750 mg and multiple doses up to 600 mg were safe and well tolerated in healthy men and women.
Stanislav Ignatenko   +7 more
wiley   +1 more source

Clusterization‐Triggered Emission from Cellulose‐Based Luminophores in Dilute Aqueous Solution through Imine Formation

open access: yesAdvanced Functional Materials, Volume 36, Issue 58, 20 July 2026.
Clusterization‐triggered emission is realized in dilute aqueous solution by introducing imine linkages into cellulose‐based luminophores. Imine functionalization creates O/N‐rich, hydrogen‐bonded clustered microenvironments that stabilize emissive states and restrict molecular motions. Luminescence is tunable by amine type and multiplicity.
Yazhou Su   +5 more
wiley   +1 more source

GCP Placement Methods for Improving the Accuracy of Shoreline Extraction in Coastal Video Monitoring

open access: yes한국해양공학회지
In coastal video monitoring, the direct linear transform (DLT) method with ground control points (GCPs) is commonly used for geo-rectification. However, current practices often overlook the impact of GCP quantity, arrangement, and the geographical ...
Changyul Lee   +3 more
doaj   +1 more source

Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 7, July 2026.
Abstract We evaluated the pharmacokinetic (PK) bioequivalence and safety of a new formulation of firsekibart (solution for injection) compared with firsekibart lyophilized powder for solution. In this randomized, double‐blind, parallel‐group study, healthy Chinese adult males received a single subcutaneous dose of 200 mg firsekibart solution for ...
Yehua Xie   +7 more
wiley   +1 more source

Assessment of Abuse Potential‐Related Effects of Oral Dried Kratom Leaf Powder in Healthy Normal Participants Following Single and Multiple Daily Doses

open access: yesDrug Testing and Analysis, Volume 18, Issue 7, Page 922-932, July 2026.
In a randomized, double‐blind, placebo‐controlled study of oral dried kratom leaf powder in healthy kratom‐naive adults, no participants met the clinically meaningful opioid withdrawal threshold; abuse‐related treatment‐emergent adverse events occurred more frequently at higher doses but were generally mild and resolved without sequelae; and no serious
Marion Coe   +5 more
wiley   +1 more source

A Community‐Led Approach to Enhancing Informed Consent for Individuals With Vision Impairment

open access: yesDiversity &Inclusion Research, Volume 3, Issue 3, July 2026.
ABSTRACT Participant Information and Consent Forms (PICFs) are critical documents that help promote informed decision‐making about research participation. However, many PICFs remain inaccessible to people with diverse needs, including those experiencing print disability.
Fleur O'Hare   +13 more
wiley   +1 more source

Structural and Functional Neuroimaging Findings in Fibromyalgia: A Systematic Review

open access: yesEuropean Journal of Pain, Volume 30, Issue 6, July 2026.
ABSTRACT Background and Objective Fibromyalgia (FM) is a nociplastic chronic pain syndrome in which neuroimaging indicates central nervous system involvement, yet findings remain inconsistent across methods. We systematically reviewed structural and functional neuroimaging studies in adults with FM to identify the most reproducible cross‐modal ...
Flávio Antônio Duboc Flutt   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy